Novartis Extends Triaminic Into Brand Name Void Left By J&J Tylenol Recall
This article was originally published in The Tan Sheet
Executive Summary
Novartis expedites a Triaminic line extension to take advantage of the branded product gap left by the recall of Johnson & Johnson's Children's Tylenol liquid OTCs
You may also be interested in...
Novartis Makes Room For OTC Division Head On Executive Committee
Novartis gives its OTC unit a direct line to the chief executive in an organizational realignment designed to strengthen and streamline the consumer businesses.
Prestige Adds Little Fevers To Children's Liquid Pain Relief Competition
Prestige Brands Holdings extends its Little Remedies pediatric OTC line with a liquid acetaminophen product, becoming the latest firm to venture into the category Johnson & Johnson usually dominates
J&J Submits McNeil Plant Reforms To FDA, Announces Layoffs
The firm submits a remediation plan for correcting quality control issues and investing in long-term improvements at its Fort Washington, Pa., plant. While the facility remains shuttered, about 75% of its positions are being eliminated and OTC production shifted elsewhere.